Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
See our 2012 Buyers Guide Digital Edition.
 
|
European Patent Office to Grant Patent for Macrocure's CureXcell?
Publish date: Mar 14, 2013
PR Newswire PETACH TIKVA, Israel, March 14, 2013 PETACH TIKVA, Israel, March 14, 2013 /PRNewswire/ -- Macrocure (http://www.macrocure.com), a biotechnology company developing advanced
cell therapy products, announced today that the European Patent Office (EPO) intends to grant a European patent covering Marcocure's
flagship product, CureXcell®. The patent will be officially granted under an application titled "Activate
Leukocyte Composition" and will provide patent coverage for CureXcell® in Europe
through March 2030. CureXcell® is a novel approach to treating hard-to-heal wounds by replenishing the imbalanced inflammatory
environment in non-healing wounds with a broad array of functionally-active allogeneic immune cells. These cells are superficially
injected into the wound bed, once a month, and release the necessary cytokines and growth factors for the wound to heal. About 5,000 patients with various types and severities of hard-to-heal wounds have been treated in Israel.
CureXcell® has been approved for reimbursement by the Israeli Ministry of Health. "The granting of a European patent for CureXcell® is a significant milestone for MacroCure, which fits
with our strategy to become a leader in the hard to heal wound treatment market in Europe,"
said Nissim Mashiach, President and CEO of Macrocure.
About Macrocure
Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies.
Macrocure is pursuing regulatory market approval in North America and Europe.
CureXcell® is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic
ulcers in adults with diabetes under SPA in the United States, Canada
and Israel. The product has marketing authorization in Israel
for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States
or Canada.
Media Contact:
SOURCE Macrocure
|
|
|
|
|
Facebook
Quizzes
